Daily Cosmetic Research Analysis
Analyzed 25 papers and selected 3 impactful papers.
Summary
Analyzed 25 papers and selected 3 impactful articles.
Selected Articles
1. Photographic Assessment of Cosmetic Outcome in Postsurgical Facial Scars Favors Rapidly Absorbable Polyglactin 910 Over Fast Absorbing Gut: A Blinded Randomized Clinical Trial.
In a blinded, split-scar randomized trial of 105 facial Mohs wounds, rapidly absorbable polyglactin 910 produced superior 6‑month photographic scar scores versus fast absorbing gut on multiple scales by a dermatologist assessor, with concordant but nonsignificant trends by a plastic surgeon. These data support choosing polyglactin 910 for facial epidermal closure to optimize cosmetic outcomes.
Impact: This adequately powered RCT with blinded assessment directly informs suture choice for facial wound closure, a common cosmetic-relevant decision in dermatologic and plastic surgery.
Clinical Implications: Prefer rapidly absorbable polyglactin 910 for facial epidermal closure after Mohs surgery to modestly improve 6‑month scar cosmesis; align expectations given interobserver variability and include shared decision-making.
Key Findings
- Split-scar, blinded RCT (n=105) comparing polyglactin 910 vs fast absorbing gut for facial epidermal closure.
- Dermatologist-assessed VAS, SBSES, and WES scores significantly favored polyglactin 910 at 6 months.
- Plastic surgeon assessments trended toward polyglactin 910 but did not reach statistical significance.
Methodological Strengths
- Randomized, split-scar design with each patient serving as internal control
- Blinded photographic assessments using multiple validated scar scales
Limitations
- Single 6-month assessment without longer-term cosmetic outcomes
- Assessor discrepancy suggests subjectivity; lack of patient-reported outcomes
Future Directions: Conduct multicenter RCTs including patient-reported outcomes and longer follow-up to validate durability and generalizability across facial subunits and skin types.
BACKGROUND: No adequately powered, randomized studies have compared different absorbable suture types used for epidermal closure on facial scar cosmesis. OBJECTIVE: To assess postsurgical facial scar appearance using rapidly absorbable polyglactin 910 or fast absorbing gut for epidermal closure. MATERIALS AND METHODS: Randomized, blinded, split-scar clinical trial of 5-0 rapidly absorbable polyglactin 910 (Vicryl Rapide) and 5-0 fast absorbing gut. Patients with facial wounds resulting from Mohs micrographic surgery (n = 105) were assigned for epidermal closure. One dermatologist and 1 plastic surgeon, blinded to original suture location, evaluated photographs of each healed scar at 6 months after surgery and graded each half of the scar using the visual analog scale (VAS), Stony Brook Scar Evaluation Scale (SBSES), and wound evaluation scale (WES). RESULTS: At 6 months, mean (SD) scores from the dermatologist all statistically favored rapidly absorbable polyglactin 910: VAS 76.5(14.5) versus 73.2(15.2), p = .05; SBSES 4.4(0.9) versus 4.0(1.1), p = .006; WES 5.4(1.0) versus 5.1(1.1), p = .05. Scores from the plastic surgeon also favored rapidly absorbable polyglactin 910 but were not statistically significant. CONCLUSION: Rapidly absorbable polyglactin 910, placed through the epidermis, was the favored absorbable suture material for facial epidermal closure.
2. Cucumber-derived exosome-like nanovesicles encapsulating epigallocatechin gallate for skin depigmentation: molecular docking, stability, and efficacy in B16/F10 cells and zebrafish.
Plant-derived exosome-like nanovesicles enabled high-efficiency (95.43%) EGCG encapsulation with improved stability and sustained release, significantly reducing tyrosinase activity and melanin in B16F10 cells and zebrafish versus free EGCG. Multi-omics and validation experiments converged on ERK–STAT3–MITF signaling, supporting a scalable, plant-based cosmetic delivery platform for depigmentation.
Impact: Introduces a mechanistically validated, plant-derived nanocarrier that overcomes EGCG instability and enhances anti-melanogenic efficacy, with clear translational potential for cosmetic formulations.
Clinical Implications: While preclinical, the platform suggests a path to more stable, potent topical depigmenting products using plant exosome-like vesicles, potentially reducing irritation by lowering required active concentrations.
Key Findings
- Hybrid PEG precipitation–electrophoretic dialysis isolation yielded high-purity CEVs with 95.43% EGCG encapsulation and sustained release.
- EGCG@CEVs reduced tyrosinase activity and melanin production more than free EGCG in B16F10 melanocytes and zebrafish.
- Mechanism implicated ERK–STAT3–MITF modulation supported by metabolomics and network pharmacology.
Methodological Strengths
- Integrated multi-omics with in vitro (B16F10) and in vivo (zebrafish) validation
- Quantitative demonstration of high encapsulation efficiency and improved stability/release kinetics
Limitations
- No human skin or clinical data to confirm efficacy/safety
- Immunogenicity and large-scale manufacturing of plant vesicles remain untested
Future Directions: Evaluate dermal penetration, irritation, and efficacy in reconstructed human skin and early-phase clinical studies; explore GMP-scale production and formulation stability.
To address the challenges of instability and low bioavailability that limit the application of (-)-epigallocatechin gallate (EGCG) as a whitening agent, we engineered a cucumber-derived exosome-like nanovesicle (CEV) as a synergistic nanocarrier. A hybrid isolation method combining polyethylene glycol precipitation with electrophoretic dialysis (PED) was established to obtain high-purity CEVs. The resulting EGCG-loaded CEVs (EGCG@CEVs) achieved 95.43% encapsulation efficiency with enhanced stability and a sustained release profile. Metabolomics and network pharmacology identified the STAT3/MAPK signaling axis as the primary target, a mechanism subsequently validated in B16F10 melanocytes and zebrafish models. Compared with free EGCG, EGCG@CEVs significantly decreased tyrosinase activity and melanin production. With the stable EGCG@CEV system, the ERK-STAT3-MITF pathway can be regulated, potentially functioning as a plant-based cosmetic system.
3. Cutaneous Variations in Stem-Cell Population in Those on GLP1-Receptor Agonists: A Comparative Controlled Study.
In vivo human adipose biopsies revealed a four-fold reduction in ADSCs (11.0 vs 44.8 cells/mm2; p=0.039) and lower CD90+ counts in GLP-1 agonist users, without changes in fibroblasts. These findings provide a mechanistic explanation for accelerated skin aging beyond weight loss and may guide regenerative treatment strategies.
Impact: First in vivo human evidence linking GLP-1 therapy to selective ADSC depletion advances mechanistic understanding of the ‘GLP-1 face’ and informs targeted regenerative approaches.
Clinical Implications: Consider earlier biostimulatory/regenerative treatments (e.g., collagen stimulators) in GLP-1 RA users; counsel patients about potential skin quality changes unrelated to weight loss alone.
Key Findings
- Significant four-fold reduction in adipose-derived stem cells in GLP-1 RA users vs controls (11.0 vs 44.8 cells/mm2; p=0.039).
- CD90+ cell counts were lower in GLP-1 users (p=0.047), while fibroblast populations were unchanged.
- Suggests selective depletion of the stem-cell compartment as a mechanism for accelerated skin aging in GLP-1 users.
Methodological Strengths
- In vivo human tissue analysis with multiplex immunofluorescence markers
- Controlled comparison with untreated controls
Limitations
- Small sample size (n=10) limits generalizability
- Cross-sectional design cannot establish temporality or causation
Future Directions: Larger longitudinal studies to track stem-cell dynamics with GLP-1 initiation and cessation; explore interventions that restore ADSC compartments.
BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists have been associated with cutaneous changes including accelerated skin aging and volume loss. The biological mechanisms underlying these effects remain poorly understood, with limited in vivo human data. OBJECTIVE: The aim of this study was to evaluate adipogenesis-associated cellular markers in subcutaneous adipose tissue of patients receiving GLP-1 receptor agonist therapy. METHODS: Abdominal adipose tissue biopsies from patients receiving GLP-1 receptor agonists and untreated controls were analyzed using multiplex immunofluorescence to quantify FSP1, CD90, CD105, CD73, and ERG and to characterize adipose-derived stem cells (ADSCs) and fibroblast populations. RESULTS: Baseline analysis of 10 adipose tissue samples demonstrated a statistically significant reduction in adipose-derived stem-cell counts in the GLP-1 group compared with controls (11.0 vs 44.8 cells/mm2, p = .039), representing an approximately four-fold decrease. CD90+ cell counts were also significantly lower in the GLP-1 group (p = .047). Fibroblast populations were not significantly different between groups, suggesting selective depletion of the stem-cell compartment. CONCLUSION: This is the first in vivo human study demonstrating a significant reduction in the ADSC population in patients on GLP-1 receptor agonist therapy. Selective depletion of ADSCs offers a potential mechanism for the accelerated skin aging changes in this population beyond weight loss alone.